Cogent Biosciences
COGT
136 hedge funds and large institutions have $1.05B invested in Cogent Biosciences in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 39 reducing their positions, and 18 closing their positions.
1,700% more call options, than puts
Call options by funds: $234K | Put options by funds: $13K
51% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 39
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
29% more capital invested
Capital invested by funds: $814M → $1.05B (+$234M)
0% more funds holding
Funds holding: 136 → 136 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
21.91% less ownership
Funds ownership: 107.6% → 85.69% (-22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.1M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$23.6M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$22.9M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.3M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.55M |
| 3 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$3.99M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$3.95M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.44M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CG
151
Cutler Group
San Francisco,
California
| – | -$2K | -200 | Closed |
|
|
EI
152
Ellevest Inc
New York
| – | -$388 | -36 | Closed |
|
153
Group One Trading
Chicago,
Illinois
| – | -$298 | -26 | Closed |
|
COGT Hedge Fund Activity: Q2 2023 in Review
136 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2023, worth a combined $1.05B — up 29% from $814M a quarter earlier.
Fund positioning in COGT was balanced in Q2 2023: 18 funds opened new positions, 18 closed out, 59 added to existing stakes and 39 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $28.1M. The largest seller was Citadel Advisors, cutting an estimated $13.3M.
- 136 institutional investors held Cogent Biosciences (COGT) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $1.05B of Cogent Biosciences stock for Q2 2023, up 29% quarter-over-quarter.
- 18 funds opened new Cogent Biosciences positions in Q2 2023 and 18 closed out, a net change of 0 holders.
- The largest Cogent Biosciences buyer in Q2 2023 was Point72 Asset Management, an estimated $28.1M added.
- The largest Cogent Biosciences seller in Q2 2023 was Citadel Advisors, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2023.